Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711693 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL4095117 | 0.87 | ALDH1A1 (0.77) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL8314773 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL19889218 | 0.82 | MEN1 (0.68) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL3281437 | 0.82 | HSD17B10 (1.00) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL4625520 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL10430902 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL8377843 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL29843133 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1PKMKMT2AHSD17B10 | |
| SCHEMBL240611 | 0.81 | MEN1 (0.68) | ALDH1A1MEN1PKMKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2012791-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007092496-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| CN-1050191-A | New thiazole derivative, they the preparation method and contain their pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | ALDH1A1 273/4885MEN1 203/4885PKM 1705/4885 |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | ALDH1A1 1021/4885MEN1 4000/4885PKM 1410/4885 |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | HSP90B1, HSP90AB2P, HSP90AB1 | ALDH1A1 2635/4885MEN1 3406/4885PKM 4448/4885 |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | KEAP1, NFE2L2, HMOX1 | ALDH1A1 1021/4885MEN1 4000/4885PKM 1410/4885 |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | ALDH1A1 1021/4885MEN1 4000/4885PKM 1410/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | ALDH1A1 273/4885MEN1 203/4885PKM 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.